Early-Phase Drug Development Is Getting Harder. Traditional CROs Weren’t Built for It.
Choosing an early-phase partner looks straightforward. It rarely is.
Promising programmes rarely stall because the science was wrong. They stall at the handoffs between consultants, labs, clinical sites and trial teams who aren’t working from the same plan. Getting early-phase right takes more than a vendor list. It takes connected scientific expertise, specialist sites and a team that has made these decisions before. Today’s sponsors are working through:
- Pressure to generate robust human data earlier, before committing to larger trials
- Go/no-go decisions that need early efficacy signals, not just safety data
- Regulatory expectations that shape the programme long before IND or CTA submission
- Handoffs between separate providers that cost time, data continuity and momentum
- Specialist populations, from renal and hepatic impairment to women’s health, that are hard to recruit predictably
hVIVO Delivers Across Early-Phase Development
This guide outlines how hVIVO’s consulting, laboratory, clinical and Human Challenge capabilities work together, so you can get on with progressing your programme.
One brochure. Every early-phase capability you need to evaluate.
Scientific Leadership
Integrated Early-Phase Ecosystem
Human Challenge Trial Expertise
Advanced Laboratory Capabilities
Bioanalytical, virology, immunology and biomarker expertise supporting work from R&D through to large Phase III studies.
Specialist Clinical Sites
Drug Development Consulting
Therapeutic Area Depth
Built by the scientific and medical leaders behind hVIVO.
The expertise in this guide comes from hVIVO’s multidisciplinary team, spanning clinical pharmacology, respiratory medicine, infectious disease, cardiometabolic research, statistics, regulatory strategy, bioanalysis and drug development consulting. Our leaders work across our sites in London, Mannheim, Kiel and Berlin to help sponsors tackle complex development challenges and generate decision-ready data.
Our Accreditations
Good Clinical Practice (GCP)
Good Clinical Practice (GCP) is an international ethical and scientific quality standard; for designing, conducting, recording and reporting trials. Ensuring participant safety prevails over the interests of science and society.

Human Tissue Authority (HTA)
hVIVO is accredited by the Human Tissue Authority (HTA), meaning that we have been recognized by the HTA as compliant with standards and regulations for the ethical and legal removal, storage, and use of human tissue. A HTA license is essential, as hVIVO handles human tissue for various research purposes.

Good Clinical Laboratory Practice (GCLP)
All clinical trials comply with GCP and/or GCP for Laboratories (GCLP) guidance. Human Challenge Agent-only clinical studies that do not involve IMP also comply with GCP/GCLP.

hVIVO is a UKAS accredited Testing Laboratory No. 27882
